EUVIMEDEUVIMED entdecken
Crossref

Assessment of prostate malignancy in participants with elevated PSA levels using transrectal ultrasound-guided prostate biopsy

Sara Yeganeh, Siavash Falahatkar, Farahnaz Joukar, Zahra Atrkar-Roshan, Fariborz Mansour-Ghanaei, Ardalan Akhavan

Middle East Journal of Noncommunicable Diseases · 29.03.2026 · 1 (1) · 1-7

DOI: 10.66224/mejncd.1.1.3 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Middle East Journal of Noncommunicable Diseases, online erschienen am 29.03.2026. Verfasst von Sara Yeganeh und 5 weiteren Autor:innen.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Prostate cancer is a common malignancy in older men and a major global health concern. This study aimed to assess prostate health and evaluate malignancy in individuals with elevated PSA levels and abnormal DRE findings.

Method

This cross-sectional study included 300 men supported by a local relief foundation and referred to Razi Hospital in 2016. Participants completed a questionnaire and underwent clinical evaluation, including digital rectal examination (DRE) and prostate-specific antigen (PSA) testing. DRE assessed asymmetry, nodules, firmness, and abnormal masses. PSA levels ≥3 ng/mL prompted further evaluation. Patients with urinary tract infection symptoms received antibiotics and repeat PSA testing. Persistently elevated PSA levels led to transrectal ultrasound-guided prostate biopsy, followed by histopathological confirmation. Univariate and multivariate regression analyses were used to identify factors associated with elevated PSA, with significance set at p < 0.05.

Results

PSA levels increased significantly with age, with participants aged ≥70 showing the highest mean values (8.2 ± 5.6 ng/mL) and more than twice the likelihood of having PSA ≥3 ng/mL (AOR = 2.18; p = 0.037). Dysuria and DRE-detected nodules showed increased odds but did not reach significance. Overall, 45 participants (15%) had PSA ≥3 ng/mL, of whom 25 underwent TRUS-guided biopsy. Histopathology confirmed malignancy in 9 cases (36%).

Conclusion

Age was the strongest predictor of PSA elevation. The borderline associations of dysuria and DRE nodules suggest potential clinical relevance, but larger studies are needed to clarify their predictive value.

Zitieren

APA

Yeganeh, S., Falahatkar, S., Joukar, F., Atrkar-Roshan, Z., Mansour-Ghanaei, F., & Akhavan, A. (2026). Assessment of prostate malignancy in participants with elevated PSA levels using transrectal ultrasound-guided prostate biopsy. Middle East Journal of Noncommunicable Diseases, 1(1), 1-7. https://doi.org/10.66224/mejncd.1.1.3

Vancouver

Yeganeh S, Falahatkar S, Joukar F, Atrkar-Roshan Z, Mansour-Ghanaei F, Akhavan A. Assessment of prostate malignancy in participants with elevated PSA levels using transrectal ultrasound-guided prostate biopsy. Middle East Journal of Noncommunicable Diseases. 2026;1(1):1-7. doi:10.66224/mejncd.1.1.3

BibTeX
@article{Yeganeh2026,
  author = {Yeganeh, Sara and Falahatkar, Siavash and Joukar, Farahnaz and Atrkar-Roshan, Zahra and Mansour-Ghanaei, Fariborz and Akhavan, Ardalan},
  title = {Assessment of prostate malignancy in participants with elevated PSA levels using transrectal ultrasound-guided prostate biopsy},
  journal = {Middle East Journal of Noncommunicable Diseases},
  year = {2026},
  volume = {1},
  number = {1},
  pages = {1--7},
  doi = {10.66224/mejncd.1.1.3}
}
Kostenlos starten →